Dubai – AGBL announced that its customer, Al Jalila Children Hospital in Dubai, has successfully completed the first sequencing of COVID-19 virus from a patient in Dubai. The sequencing was performed by researchers from Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) using Illumina sequencing technology. The next generation sequencers were supplied and are currently supported by AGBL.
AGBL’s Sales Director, Fady Al Assaly, expressed his company’s ongoing commitment to support governments and healthcare providers across the region in the global fight against COVID-19, “The news about our customers, Al Jalila Children and MBRU, sequencing the COVID-19 virus in the UAE pleases us greatly. This comes as part of our continuing efforts to support customers across the region in supplying and supporting testing labs for the detection and sequencing of COVID-19. We believe there will be much more news about these efforts in the near future.”
-Ends-
About AGBL
AGBL Group of companies is the largest biomedical distribution group in the Middle East, Africa, and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic centres in emerging healthcare markets. www.agbl.net
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
